Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116441 · ClinicalTrials.gov registry record · Phase 1
Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma
A Phase 1 study, sponsored by Cell Genesys.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00116441: Completed Phase 1 study, sponsored by Cell Genesys.
NCT00116441 is a Phase 1 study that has completed, run by Cell Genesys. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116441, a Phase 1 study, has completed, sponsored by Cell Genesys.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.
Interventions
- BIOLOGICAL Therapeutic Cellular Vaccine, GM-CSF Producing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2000-10 |
| Est. Completion | 2004-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116441
The ClinicalTrials.gov registry entry for NCT00116441 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cell Genesys, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Therapeutic Cellular Vaccine, GM-CSF Producing is the first listed.
NCT00116441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116441 about?
NCT00116441 is a clinical study titled "Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma". The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.
What is the current status of trial NCT00116441?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2000-10. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00116441?
The interventions under investigation include: Therapeutic Cellular Vaccine, GM-CSF Producing (BIOLOGICAL).
Who is sponsoring clinical trial NCT00116441?
This trial is sponsored by Cell Genesys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.